Antagonists of the A2B adenosine receptor may cause effects, such as increased insulin release [7,8], reduced insulin resistance, decreased fat accumulation in the liver [7], reduced liver glucose production, improved glucose disposal into skeletal muscles and brown adipose tissue in diabetic mice [12], inhibition of the progression of renal fibrosis derived from diabetes [13], induction of anti-inflammatory effects [7,14], and reduction of IL-6 levels [14,15]. Here, INS is linked to diabetes mellitus.